Farouk, M., Zahra, O., Soliman, M., Ibrahim, H. (2023). STUDY THE PROGNOSTIC VALUE OF INFLAMMATORY BLOOD MARKER FOR OVERALL SURVIVAL IN NON-METASTATIC BREAST CANCER. ALEXMED ePosters, 5(3), 42-43. doi: 10.21608/alexpo.2023.230446.1674
Mohamed Farouk; Omar Shebl Zahra; Maher Mohammed Soliman; Hoda Gamal Nasr Sakr Ibrahim. "STUDY THE PROGNOSTIC VALUE OF INFLAMMATORY BLOOD MARKER FOR OVERALL SURVIVAL IN NON-METASTATIC BREAST CANCER". ALEXMED ePosters, 5, 3, 2023, 42-43. doi: 10.21608/alexpo.2023.230446.1674
Farouk, M., Zahra, O., Soliman, M., Ibrahim, H. (2023). 'STUDY THE PROGNOSTIC VALUE OF INFLAMMATORY BLOOD MARKER FOR OVERALL SURVIVAL IN NON-METASTATIC BREAST CANCER', ALEXMED ePosters, 5(3), pp. 42-43. doi: 10.21608/alexpo.2023.230446.1674
Farouk, M., Zahra, O., Soliman, M., Ibrahim, H. STUDY THE PROGNOSTIC VALUE OF INFLAMMATORY BLOOD MARKER FOR OVERALL SURVIVAL IN NON-METASTATIC BREAST CANCER. ALEXMED ePosters, 2023; 5(3): 42-43. doi: 10.21608/alexpo.2023.230446.1674
STUDY THE PROGNOSTIC VALUE OF INFLAMMATORY BLOOD MARKER FOR OVERALL SURVIVAL IN NON-METASTATIC BREAST CANCER
2Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University
3Department of Clinical Oncology, Faculty of Medicine, University of Alexandria
Abstract
The role of the host immunological and inflammatory responses in the tumor's microenvironment for the initiation and spread of cancer has been demonstrated in multiple studies, therefore based on the spatial distribution of immune cells in the tumor microenvironment, tumors can be divided into hot tumors and cold tumors. The systemic inflammatory reaction brought on by a tumor leads to alterations of peripheral blood white blood cells, As a consequence, the association between inflammatory cells in the peripheral blood may offer an accessible and early method to assess the prognosis of a patient through Inflammatory blood marker such as neutrophil lymphocyte ration NLR and platelets lymphocyte ration PLR. Aim of the Work: The present study aimed to determine the prognostic value of the NLR and PLR to predict OS and DFS among non-metastatic breast cancer patients. Patient and Methods: 348 patients pathological and radiological proven to be non-metastatic breast cancer were reviewed retrospectively, autoimmune and hematological diseases were excluded.